EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Antibody isotype epitope mapping of SARS‐CoV‐2 Spike RBD protein: Targets for COVID‐19 symptomatology and disease control

Marinela Contreras, Joaquín Vicente, José Joaquín Cerón, Silvia Martinez Subiela, José Miguel Urra iD, Francisco J Rodríguez-Del-Río, Elisa Ferreras-Colino, Rita Vaz-Rodrigues, Isabel G de Fernández de Mera, Sandra Antunes, Ana Domingos, Christian Gortázar und 1 weitere

European Journal of Immunology · 2023

DOI: 10.1002/eji.202250206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Immunology, 2023. Verfasst von Marinela Contreras und 12 weiteren Autor:innen. Beteiligte Einrichtung: SaBio, Instituto de Investigación en Recursos Cinegéticos IREC-CSIC-UCLM-JCCM, Ronda de Toledo s/n, Ciudad Real, Spain. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) still poses a challenge for biomedicine and public health. To advance the development of effective diagnostic, prognostic, and preventive interventions, our study focused on high‐throughput antibody binding epitope mapping of the SARS‐CoV‐2 spike RBD protein by IgA, IgM and IgG antibodies in saliva and sera of different cohorts from healthy uninfected individuals to SARS‐CoV‐2‐infected unvaccinated and vaccinated asymptomatic, recovered, nonsevere, and severe patients. Identified candidate diagnostic (455‐LFRKSNLKPFERD‐467), prognostic (395‐VYADSFVIRGDEV‐407‐C‐KLH, 332‐ITNLCPFGEV‐342‐C‐KLH, 352‐AWNRKRI‐358‐C‐KLH, 524‐VCGPKKSTNLVKN‐536‐KLH), and protective (MKLLE‐487‐NCYFPLQSYGFQPTNGVG‐504‐GGGGS‐446‐GGNYNYLYRLFRKSNLKPFERD‐467) epitopes were validated with sera from prevaccine and postvaccine cohorts. The results identified neutralizing epitopes and support that antibody recognition of linear B‐cell epitopes in RBD protein is associated with antibody isotype and disease symptomatology. The findings in asymptomatic individuals suggest a role for anti‐RBD antibodies in the protective response against SARS‐CoV‐2. The possibility of translating results into diagnostic interventions for the early diagnosis of asymptomatic individuals and prognosis of disease severity provides new tools for COVID‐19 surveillance and evaluation of risks in hospitalized patients. These results, together with other approaches, may contribute to the development of new vaccines for the control of COVID‐19 and other coronavirus‐related diseases using a quantum vaccinomics approach through the combination of protective epitopes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansAntibodies, NeutralizingAntibodies, ViralEpitope MappingEpitopes, B-LymphocyteSARS-CoV-2Spike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

antibody isotypeepitope mappingprognostic, SARS-CoV-2spike protein

Substanzen

Antibodies, NeutralizingAntibodies, ViralEpitopes, B-Lymphocytespike protein, SARS-CoV-2Spike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • SaBio, Instituto de Investigación en Recursos Cinegéticos IREC-CSIC-UCLM-JCCM, Ronda de Toledo s/n, Ciudad Real, Spain.
  • Interdisciplinary Laboratory of Clinical Analysis, Interlab-UMU, Regional Campus of International Excellence Campus Mare Nostrum, University of Murcia, Murcia, Espinardo, Spain.
  • Immunology, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.
  • Medicine School, Universidad de Castilla la Mancha (UCLM), Ciudad Real, Spain.
  • Local Medical Service Horcajo de los Montes, Ciudad Real, Spain.
  • Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal.

ORCID-Profile: José Miguel Urra, José de la Fuente

Zitieren

APA

Contreras, M., Vicente, J., Cerón, J. J., Martinez Subiela, S., Urra, J. M., Rodríguez-Del-Río, F. J., Ferreras-Colino, E., Vaz-Rodrigues, R., de Fernández de Mera, I. G., Antunes, S., Domingos, A., Gortázar, C., & de la Fuente, J. (2023). Antibody isotype epitope mapping of SARS‐CoV‐2 Spike RBD protein: Targets for COVID‐19 symptomatology and disease control. European Journal of Immunology. https://doi.org/10.1002/eji.202250206

Vancouver

Contreras M, Vicente J, Cerón JJ, Martinez Subiela S, Urra JM, Rodríguez-Del-Río FJ, et al. Antibody isotype epitope mapping of SARS‐CoV‐2 Spike RBD protein: Targets for COVID‐19 symptomatology and disease control. European Journal of Immunology. 2023. doi:10.1002/eji.202250206

BibTeX
@article{Contreras2023,
  author = {Contreras, Marinela and Vicente, Joaquín and Cerón, José Joaquín and Martinez Subiela, Silvia and Urra, José Miguel and Rodríguez-Del-Río, Francisco J and Ferreras-Colino, Elisa and Vaz-Rodrigues, Rita and de Fernández de Mera, Isabel G and Antunes, Sandra and Domingos, Ana and Gortázar, Christian and de la Fuente, José},
  title = {Antibody isotype epitope mapping of SARS‐CoV‐2 Spike RBD protein: Targets for COVID‐19 symptomatology and disease control},
  journal = {European Journal of Immunology},
  year = {2023},
  doi = {10.1002/eji.202250206}
}
Kostenlos starten →